pexapral 315mg tableta s prodlouženým uvolňováním - otsingu tulemused

hikma pharmaceuticals usa inc. - doxapram hydrochloride (unii: p5ru6uoq5y) (doxapram - unii:94f3830q73) - doxapram hydrochloride 20 mg in 1 ml - - when the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. - to pharmacologically stimulate deep breathing in the postoperative patient. (a quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and cns depression due to drug overdosage. doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. its use should be for a short period of time (see dosage and administration ) as an aid in the prevention of elevation of arterial co2 tension during the administration of oxygen. it should not be used in conjunction with mechanical ventilation. doxapram is contraindicated in patients with known hypersensitivity to the drug or any of the injection components. doxapram should not be used in patients with epilepsy or other convulsive disorders. doxapram is contraindicated in patients with proven or suspected pulmonary embolism. doxapram is contraindicated in patients with mechanical disorders of ventilation such as mechanical obstruction, muscle paresis (including neuromuscular blockade), flail chest, pneumothorax, acute bronchial asthma, pulmonary fibrosis, or other conditions resulting in restriction of the chest wall, muscles of respiration, or alveolar expansion. doxapram is contraindicated in patients with evidence of head injury, cerebral vascular accident, or cerebral edema, and in those with significant cardiovascular impairment, uncompensated heart failure, severe coronary artery disease, or severe hypertension, including that associated with hyperthyroidism or pheochromocytoma. (see warnings .)